<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="common cause of death in the extremely old subject. During" exact="infection" post="and its complication such as sepsis, hypotension could be"/>
 <result pre="is no evidence that RAS inhibitors are harmful during COVID-19" exact="infection" post="and have in fact been shown to be beneficial"/>
 <result pre="specific infection, septic shock, and/or organ failure. General aspects of" exact="infection" post="and hypertension management There are some general aspects in"/>
 <result pre="relation to hypertension management or antihypertensive drug use when some" exact="infection" post="is impending or ongoing. First of all, because hypertension"/>
 <result pre="modulation can be a signal for sepsis in patient with" exact="infection" post="[2]. Some mediators to suppress sympathetic nervous system may"/>
 <result pre="there is no evidence to stop using these drugs in" exact="infection" post="patients unless they are associated with hemodynamic instability. However,"/>
 <result pre="with acute hypotension, acute kidney injury, or hyperkalemia related to" exact="infection" post="[6]. Besides the toxin supplied by infectious organisms, catecholamine"/>
 <result pre="hemodynamic instability or hypotension is a serious condition during acute" exact="infection" post="which requires stopping or adjustment of antihypertensive drug dosage"/>
 <result pre="adjusted according to the general and hemodynamic conditions only after" exact="infection" post="begins and it will be only temporary even when"/>
 <result pre="issue about adjustment of antihypertensive drug use to protect from" exact="infection" post="preemptively because there is no direct involvement of antihypertensive"/>
 <result pre="the elderly and those with comorbidities. In particular, the high" exact="prevalence" post="of hypertension and diabetes suggests that they maybe risk"/>
 <result pre="suggests that they maybe risk factors for severe COVID-19. The" exact="prevalence" post="of hypertension is apparently high in patients with severe"/>
 <result pre="COVID-19, however, considering the age of those patients, the actual" exact="prevalence" post="of hypertension does not seem to be higher. Zhou"/>
 <result pre="the average age of deaths (nâ€‰=â€‰54) was 69â€‰years, and the" exact="prevalence" post="of hypertension was 48%, which is quite comparable to"/>
 <result pre="of hypertension was 48%, which is quite comparable to the" exact="prevalence" post="of hypertension in the representative population of those ages"/>
 <result pre="clinical features of 1099 COVID-19 patients diagnosed in Wuhan, the" exact="prevalence" post="of hypertension was higher in severe patients (Nâ€‰=â€‰173, mean"/>
 <result pre="13.4%), but it was not particularly higher when considering the" exact="prevalence" post="of hypertension in that age group [11]. Therefore, there"/>
 <result pre="that hypertension itself is an independent risk factor for severe" exact="infection" post="or mortality by COVID-19. The higher prevalence of hypertension"/>
 <result pre="factor for severe infection or mortality by COVID-19. The higher" exact="prevalence" post="of hypertension in patients with COVID-19 is more likely"/>
 <result pre="make the patient much more vulnerable to progression to severe" exact="infection" post="or death. In 2004, since the SARS-CoV-1 outbreak in"/>
 <result pre="in theory, make the patient vulnerable to lower respiratory tract" exact="infection" post="or viral pneumonia [12, 13]. Since the COVID-19 outbreak,"/>
 <result pre="exacerbates corona virus infection, obvious increase in mortality and severe" exact="infection" post="in patients receiving RAS inhibitor should have been reported"/>
 <result pre="in vivo studies have shown that decreased ACE2 during SARS-CoV-1" exact="infection" post="exacerbated acute lung injury. Imai et al. conducted experiments"/>
 <result pre="a protective effect against acute lung injury caused by SARS-CoV-1" exact="infection" post="(Fig 1, b). Given that COVID-19 has similar pathophysiological"/>
 <result pre="ACE2 or RAS blockade might even be protective against severe" exact="infection" post="or death. Fig. 1 Angiotensin Converting Enzyme 2 in"/>
 <result pre="ACE2, TMPRSS2, and ADAM17 in lung epithelial cells. In SARS-CoV-1" exact="infection" post="and presumably in SARS-CoV-2 infection, binding of spike protein"/>
 <result pre="The type II transmembrane serine proteases In summary, 1) the" exact="prevalence" post="of hypertension in patients with severe COVID-19 is high."/>
 <result pre="evidence that hypertension is an independent risk factor for severe" exact="infection" post="or death until proven otherwise. 2) Regarding the concerns"/>
 <result pre="otherwise. 2) Regarding the concerns for increased risk of severe" exact="infection" post="or death due to the theoretical concerns that taking"/>
 <result pre="to be maintained on RAS blockade 2) In hemodynamically stable," exact="treatment" post="naÃ¯ve patients who have compelling indication for using RAS"/>
 <result pre="class. Also, the use of RAS blockade SARS-CoV-2 pandemic before" exact="infection" post="should be maintained based on the current scientific knowledge."/>
 <result pre="for the use of antihypertensive drugs before and during severe" exact="infection" post="or epidemics. Publisherâ€™s Note Springer Nature remains neutral with"/>
</results>
